Theranostics
13.3
Impact Factor
23.90
CiteScore
< 5 days
First Decision
Global reach, higher impact
Theranostics 2021; 11(8):3963. doi:10.7150/thno.58558 This issue Cite
Erratum
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum
Jiang-Kai Dong1,2,#, Hui-Min Lei1,2,#, Qian Liang1,2,#, Ya-Bin Tang1,2, Ye Zhou1,2, Yang Wang1,2, Shengzhe Zhang3, Wen-Bin Li1, Yunguang Tong4,5, Guanglei Zhuang3, Liang Zhang1,2, Hong-Zhuan Chen1,2, 
, Liang Zhu1,2, , Ying Shen1,2,
1. Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
2. Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China
3. State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
4. Basic Medical College, Xinxiang Medical University, Xinxiang 453003, Henan, China
5. Department of Medicine, Cedars-Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, CA 90048, United States
#These authors contributed equally to the manuscript
Published 2021-2-9
Citation:
Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, Zhang S, Li WB, Tong Y, Zhuang G, Zhang L, Chen HZ, Zhu L, Shen Y. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum. Theranostics 2021; 11(8):3963. doi:10.7150/thno.58558. https://www.thno.org/v11p3963.htm
Other stylesCorrected-article in Theranostics, Volume 8, 1808
“HCC827ER9” was inadvertently mistyped as “HCC827ER4” in Figure 1D. The correction has now been made online. This corrigendum does not affect any results or conclusions of the paper. The authors sincerely apologize for any confusion and inconvenience may have caused.
Figure 1
D. Corrected image
Author contact
Corresponding authors: Ying Shen, Ph.D, Associate Research Fellow, Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Ph: 008621-63846590; Fax: 008621-54561329; Email: yshen0510edu.cn; Liang Zhu, Ph.D, Professor, Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Ph: 008621-63846590; Fax: 008621-54561329; Email: zhuliang17com; Hong-Zhuan Chen, Ph.D, Professor, Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Ph: 008621-63846590; Fax: 008621-54561329; Email: hongzhuan_chencom
Citation styles
APA
Dong, J.K., Lei, H.M., Liang, Q., Tang, Y.B., Zhou, Y., Wang, Y., Zhang, S., Li, W.B., Tong, Y., Zhuang, G., Zhang, L., Chen, H.Z., Zhu, L., Shen, Y. (2021). Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum. Theranostics, 11(8), 3963. https://doi.org/10.7150/thno.58558.
ACS
Dong, J.K.; Lei, H.M.; Liang, Q.; Tang, Y.B.; Zhou, Y.; Wang, Y.; Zhang, S.; Li, W.B.; Tong, Y.; Zhuang, G.; Zhang, L.; Chen, H.Z.; Zhu, L.; Shen, Y. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum. Theranostics 2021, 11 (8), 3963. DOI: 10.7150/thno.58558.
NLM
Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, Zhang S, Li WB, Tong Y, Zhuang G, Zhang L, Chen HZ, Zhu L, Shen Y. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum. Theranostics 2021; 11(8):3963. doi:10.7150/thno.58558. https://www.thno.org/v11p3963.htm
CSE
Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, Zhang S, Li WB, Tong Y, Zhuang G, Zhang L, Chen HZ, Zhu L, Shen Y. 2021. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum. Theranostics. 11(8):3963.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.